🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Surgery Partners executive sells $158k in company stock

Published 06/13/2024, 05:34 PM
SGRY
-

Surgery Partners, Inc. (NASDAQ:SGRY) reported that Danielle Burkhalter, the company's Chief Human Resources Officer, sold 6,000 shares of company stock on June 12, 2024, for a total value of $158,310 at an average price of $26.385 per share.

The transaction was disclosed in a filing with the Securities and Exchange Commission. Following the sale, Burkhalter's direct ownership in Surgery Partners stands at 30,354 shares. The sale occurred as part of a planned transaction by the executive, as indicated by the company's filing.

Surgery Partners, Inc. is known for providing healthcare services and operates surgical facilities across the United States. The sale by a top executive might be of interest to investors who track insider transactions as a gauge of management's confidence in the company's prospects.

Investors and shareholders of Surgery Partners can access the details of the transaction through the company's SEC filings. The stock sale represents a routine financial move and the details provided offer transparency about executive stock ownership changes.

The company's shares traded on the NASDAQ under the ticker symbol SGRY and the recent transactions by company executives are publicly available for review by investors and regulatory bodies.

In other recent news, Surgery Partners, a leading healthcare services provider, has reported robust first-quarter growth for 2024. The company's net revenues reached approximately $717 million, marking a 7.7% increase year-over-year. The growth was even more significant on a same-facility basis, with a 10.2% rise. Adjusted EBITDA for the quarter was $97.5 million, an 8.2% increase from the prior year.

In addition to its financial performance, Surgery Partners recently held its 2024 Annual Meeting of Stockholders, where several key proposals were approved. These included the election of directors, executive compensation, and an employee stock purchase plan. The company also ratified the appointment of Deloitte & Touche LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024.

Looking ahead, Surgery Partners has raised its full-year net revenue and adjusted EBITDA forecasts to at least $3.05 billion and $505 million, respectively. The company also anticipates closing on $200 million to $250 million in acquisitions in the second quarter. Despite a revenue decrease of $36 million from divested facilities and uncertainty in Medicaid reimbursement and state tax policy, the company expects to exceed the 2% to 3% volume growth target for the year. These are recent developments that underscore the company's strong Q1 performance and positive outlook for the year.

InvestingPro Insights

Surgery Partners, Inc. (NASDAQ:SGRY) has been navigating a dynamic market landscape, and recent insider trading activity may prompt investors to look closely at the company's financial health and future prospects. According to the latest InvestingPro data, Surgery Partners boasts a market capitalization of $3.21 billion. Despite the insider sale, the company has shown a revenue growth of 7.1% over the last twelve months as of Q1 2024, indicating a steady upward trend in its financial performance.

InvestingPro Tips suggest that Surgery Partners is expected to see net income growth this year, which could be a positive sign for investors considering the recent insider sale. Additionally, the company has been profitable over the last twelve months and analysts predict it will remain profitable this year. This could be a signal of underlying strength in Surgery Partners' business model and operational efficiency, potentially reassuring investors following the insider transaction.

However, potential investors should be aware of the high earnings multiple, with an adjusted P/E ratio as of Q1 2024 at a substantial 3595.49, which might be a point of concern as it indicates that the stock is trading at a premium compared to earnings. Moreover, the company's stock price movements have been quite volatile, with a 1-year price total return of -31.93%, highlighting the need for cautious investment strategies.

For those seeking to delve deeper into Surgery Partners' financials and gain more insights, InvestingPro offers additional tips. There are currently 6 more InvestingPro Tips available, which can be accessed at https://www.investing.com/pro/SGRY. These tips could offer valuable guidance in making informed investment decisions.

Investors interested in leveraging these insights can take advantage of an exclusive offer using coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. This could be an opportune time to access in-depth analysis and real-time data that can help navigate the complexities of investing in healthcare service providers like Surgery Partners.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.